Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.
作者信息
Price Diana L, Khan Asma, Angers Rachel, Cardenas Alvaro, Prato Maria Key, Bani Massimo, Bonhaus Douglas W, Citron Martin, Biere Anja-Leona
机构信息
Neuropore Therapies, Inc., San Diego, CA, USA.
UCB Biopharma SPRL, Braine l'Alleud, Belgium.
出版信息
NPJ Parkinsons Dis. 2024 Mar 14;10(1):60. doi: 10.1038/s41531-024-00658-6.
Abstract
摘要
相似文献
1
Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.对相关问题的回复：α-突触核蛋白错误折叠抑制剂minzasolmin的体内效应支持其在帕金森病中的临床开发。
NPJ Parkinsons Dis. 2024 Mar 14;10(1):60. doi: 10.1038/s41531-024-00658-6.
2
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.相关事宜：α-突触核蛋白错误折叠抑制剂明扎索尔明的体内效应支持其在帕金森病中的临床开发。
NPJ Parkinsons Dis. 2024 Mar 14;10(1):59. doi: 10.1038/s41531-024-00657-7.
3
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.α-突触核蛋白错误折叠抑制剂明扎索尔明的体内效应支持帕金森病的临床开发。
NPJ Parkinsons Dis. 2023 Jul 17;9(1):114. doi: 10.1038/s41531-023-00552-7.
4
Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy.鉴别帕金森病和多系统萎缩中的α-突触核蛋白菌株。
Nature. 2020 Feb;578(7794):273-277. doi: 10.1038/s41586-020-1984-7. Epub 2020 Feb 5.
5
Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.帕金森病的诊断生物标志物：聚焦于脑脊液中的 α-突触核蛋白。
Parkinsonism Relat Disord. 2019 Feb;59:21-25. doi: 10.1016/j.parkreldis.2018.11.016. Epub 2018 Nov 15.
6
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.针对帕金森病中 alpha-synuclein 的诊断和治疗药物。
J Neurol. 2022 Nov;269(11):5762-5786. doi: 10.1007/s00415-022-11267-9. Epub 2022 Jul 13.
7
Parkinson's disease, cortical dysfunction, and alpha-synuclein.帕金森病、皮质功能障碍与α-突触核蛋白。
Mov Disord. 2011 Jul;26(8):1436-42. doi: 10.1002/mds.23697. Epub 2011 May 3.
8
Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease.了解 alpha-突触核蛋白功能的进展：对帕金森病的影响。
Brain. 2023 Sep 1;146(9):3587-3597. doi: 10.1093/brain/awad150.
9
α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling.α-突触核蛋白错误折叠与聚集：与帕金森病的相关性——批判性评估与建模
Mol Neurobiol. 2015;51(3):1417-31. doi: 10.1007/s12035-014-8818-2. Epub 2014 Aug 20.
10
Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.形态异常：α-突触核蛋白错误折叠与帕金森病致病途径的汇聚
FEBS Lett. 2015 Dec 21;589(24 Pt A):3749-59. doi: 10.1016/j.febslet.2015.10.023. Epub 2015 Oct 23.
本文引用的文献
1
Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).评估和应用一种 PET 示踪剂在临床前和 I 期研究中，以确定 Minzasolmin（UCB0599）在大脑中的生物分布。
Mol Imaging Biol. 2024 Apr;26(2):310-321. doi: 10.1007/s11307-023-01878-7. Epub 2023 Dec 18.
2
The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease.α-突触核蛋白在中枢神经系统中与脂质的双向相互作用及其对帕金森病发病机制的影响。
Int J Mol Sci. 2023 Aug 26;24(17):13270. doi: 10.3390/ijms241713270.
3
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.α-突触核蛋白错误折叠抑制剂明扎索尔明的体内效应支持帕金森病的临床开发。
NPJ Parkinsons Dis. 2023 Jul 17;9(1):114. doi: 10.1038/s41531-023-00552-7.
4
α-Synuclein and biological membranes: the danger of loving too much.α-突触核蛋白与生物膜：爱之深，忧之切。
Chem Commun (Camb). 2023 Jul 13;59(57):8769-8778. doi: 10.1039/d3cc01682j.
5
High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599.膜结合型 α-突触核蛋白的高分辨率结构信息为抗帕金森病药物 UCB0599 的作用机制提供了深入了解。
Proc Natl Acad Sci U S A. 2023 Apr 11;120(15):e2201910120. doi: 10.1073/pnas.2201910120. Epub 2023 Apr 7.
6
Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.UCB0599 的 1/1b 期研究，一种 α-突触核蛋白错误折叠的口服抑制剂，包括帕金森病的随机研究。
Mov Disord. 2022 Oct;37(10):2045-2056. doi: 10.1002/mds.29170. Epub 2022 Aug 12.
7
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.小分子α-突触核蛋白错误折叠抑制剂 NPT200-11 在帕金森病动物模型中产生多种益处。
Sci Rep. 2018 Nov 1;8(1):16165. doi: 10.1038/s41598-018-34490-9.
8
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.过度表达野生型人α-突触核蛋白的小鼠早期和进行性感觉运动异常。
J Neurosci. 2004 Oct 20;24(42):9434-40. doi: 10.1523/JNEUROSCI.3080-04.2004.
9
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.在帕金森病家族中鉴定出的α-突触核蛋白基因突变。
Science. 1997 Jun 27;276(5321):2045-7. doi: 10.1126/science.276.5321.2045.
Zotero 插件